Luan Shuxin, Wan Hongquan, Wang Shijun, Li He, Zhang Baogang
Department of Mental Health.
Department of Pain Medicine, The First Hospital of Jilin University.
Neuropsychiatr Dis Treat. 2017 Feb 27;13:609-620. doi: 10.2147/NDT.S127453. eCollection 2017.
Whether olanzapine/fluoxetine combination (OFC) is superior to olanzapine or fluoxetine monotherapy in patients with treatment-resistant depression (TRD) remains controversial. Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of OFC with olanzapine or fluoxetine monotherapy for patients with TRD.
RCTs published in PubMed, Embase, Web of Science, and the ClinicalTrials.gov registry were systematically reviewed to assess the efficacy and safety of OFC. Outcomes included mean changes from baseline in Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), Brief Psychiatric Rating Scale (BPRS) scores, response rate, remission rate, and adverse events. Results were expressed with weighted mean difference (WMD) with 95% confidence intervals (CIs) and risk ratio (RR) with 95% CIs.
A total of five RCTs with 3,020 patients met the inclusion criteria and were included in this meta-analysis. Compared with olanzapine or fluoxetine monotherapy, OFC was associated with greater changes from baseline in MADRS (WMD =-3.37, 95% CI: -4.76, -1.99; <0.001), HAM-A (WMD =-1.82, 95% CI: -2.25, -1.40; <0.001), CGI-S (WMD =-0.37, 95% CI: -0.45, -0.28; <0.001), and BPRS scores (WMD =-1.46, 95% CI: -2.16, -0.76; <0.001). Moreover, OFC had significantly higher response rate (RR =1.35, 95% CI: 1.12, 1.63; =0.001) and remission rate (RR =1.71, 95% CI: 1.31, 2.23; <0.001). The incidence of treatment-related adverse events was similar between the OFC and monotherapy groups (RR =1.01, 95% CI: 0.94, 1.08; =0.834).
OFC is more effective than olanzapine or fluoxetine monotherapy in the treatment of patients with TRD. Our results provided supporting evidence for the use of OFC in TRD. However, considering the limitations in this study, more large-scale, well-designed RCTs are needed to confirm these findings.
对于难治性抑郁症(TRD)患者,奥氮平/氟西汀联合用药(OFC)是否优于奥氮平或氟西汀单药治疗仍存在争议。因此,我们进行了这项随机对照试验(RCT)的荟萃分析,以比较OFC与奥氮平或氟西汀单药治疗TRD患者的疗效和安全性。
系统回顾了发表在PubMed、Embase、Web of Science和ClinicalTrials.gov注册库中的RCT,以评估OFC的疗效和安全性。结局指标包括蒙哥马利-艾斯伯格抑郁量表(MADRS)、临床总体印象-严重程度(CGI-S)、汉密尔顿焦虑量表(HAM-A)、简明精神病评定量表(BPRS)评分从基线的平均变化、缓解率、治愈率和不良事件。结果以加权平均差(WMD)及95%置信区间(CI)和风险比(RR)及95%CI表示。
共有5项RCT、3020例患者符合纳入标准并纳入本荟萃分析。与奥氮平或氟西汀单药治疗相比,OFC与MADRS(WMD = -3.37,95%CI:-4.76,-1.99;<0.001)、HAM-A(WMD = -1.82,95%CI:-2.25,-1.40;<0.001)、CGI-S(WMD = -0.37,95%CI:-0.45,-0.28;<0.001)和BPRS评分(WMD = -1.46,95%CI:-2.16,-0.76;<0.001)从基线的更大变化相关。此外,OFC的缓解率(RR = 1.35,95%CI:1.12,1.63;= 0.001)和治愈率(RR = 1.71,95%CI:1.31,2.23;<0.001)显著更高。OFC组和单药治疗组治疗相关不良事件的发生率相似(RR = 1.01,95%CI:0.94,1.08;= 0.834)。
OFC在治疗TRD患者方面比奥氮平或氟西汀单药治疗更有效。我们的结果为OFC用于TRD提供了支持性证据。然而,考虑到本研究的局限性,需要更多大规模、设计良好的RCT来证实这些发现。